Genetically Modified Cells TRIZ Cases

A serum-free cell culture medium supplements ornithine and putrescine to enhance protein production in animal cell lines.

Automated isolation of induced pluripotent stem cells uses selective binding to remove viral vector integration, reducing manual sub-cloning time.

Genetically modified stem cells deliver suicide genes and immune checkpoint inhibitors directly to tumor sites.

Mutated CD117 variants preserve normal hematopoiesis while allowing specific elimination of cancer cells expressing wild-type antigens.

Controlled agitation and periodic medium exchange maintain high cell densities while minimizing shear stress damage.

Transposon vectors integrate gene fragments into mammalian cell chromosomes, reducing time to establish productive cell lines.

A method for selecting stable recombinant protein producing cell clones by measuring specific marker gene expression levels using quantitative RT-PCR.

Cre-recombinase mediated cassette exchange accelerates reporter line development while maintaining isogenic background consistency across diverse cell lines.

Transfecting acinar cells with a GnT-V plasmid promotes stemness and enables transdifferentiation into functional insulin-secreting cells.

Polydonor CD4+ T cells expressing IL-10 bypass autologous production delays, enabling scalable therapy for graft-versus-host disease.

Synthetic transcription factors modulate endogenous gene expression to drive nuclear reprogramming.

Optimized suspension culture with GSK3β inhibitors and bFGF maintains neural crest cell multipotency during long-term proliferation.

A permanent human cell line enables high-yield transient protein expression through episomal plasmid replication.

A site-directed integration method generates production-competent cell banks with consistent transcription rates.

Re-cloning monoclonal cell lines with optimized selection agents increases therapeutic protein productivity while maintaining quality attributes.

Placental stem cells suppress tumor growth by 20-95% through direct contact, resolving the lack of prior descriptions for this therapeutic approach.

Simultaneous co-electroporation merges viral vector insertion with electroporation, reducing cell stress and maintaining viability above 50%.

TPM1 inhibitors boost megakaryocyte yields from stem cells, addressing insufficient platelet supply for clinical demand.